Welcome to LookChem.com Sign In|Join Free

CAS

  • or

393509-21-2

Post Buying Request

393509-21-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

393509-21-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 393509-21-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,9,3,5,0 and 9 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 393509-21:
(8*3)+(7*9)+(6*3)+(5*5)+(4*0)+(3*9)+(2*2)+(1*1)=162
162 % 10 = 2
So 393509-21-2 is a valid CAS Registry Number.
InChI:InChI=1/C15H16FNO2/c1-2-19-14(18)7-9-3-5-11-12-8-10(16)4-6-13(12)17-15(9)11/h4,6,8-9,17H,2-3,5,7H2,1H3

393509-21-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 2-(7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate

1.2 Other means of identification

Product number -
Other names Cyclopent[b]indole-3acetic acid,7-fluoro-1,2,3,4-tetrahydro-,ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:393509-21-2 SDS

393509-21-2Relevant articles and documents

Method of Treating Pathological Blushing

-

Page/Page column 12, (2010/11/29)

A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

-

Page/Page column 42, (2008/06/13)

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

-

Page/Page column 75, (2010/11/08)

The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 393509-21-2